Navigation Links
Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
Date:7/18/2011

PHILADELPHIA, July 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP; NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult patients. This approval follows the previous indication of Lialda approved by the FDA in 2007 for the induction of remission in patients with active, mild to moderate ulcerative colitis.

"At Shire, we strive to create meaningful therapies for patients with our clinical programs, and this approval based on our large clinical trial underscores our commitment and dedication to the ulcerative colitis community," said Roger Adsett, Senior Vice President of Shire's Gastrointestinal business. "This new indication is an important milestone for Lialda as it provides a once-daily option for both inducing remission in patients with active, mild to moderate ulcerative colitis and maintaining remission of ulcerative colitis."  

Lialda's new indication is based on results from a multicenter, randomized, double-blind, active comparator, non-inferiority study conducted in 826 adult patients in remission from ulcerative colitis. Maintenance of remission was assessed using a modified Ulcerative Colitis Disease Activity Index (UC-DAI) and was based on maintaining endoscopic remission defined as a modified UC-DAI endoscopy subscore of less than or equal to 1. The endoscopy subscore of less than or equal to 1 represented normal or mild disease with no friability.

Of the patients receiving Lialda 2.4 g/day (n=343) administered once daily, 83.7% maintained remission at Month 6, which was similar to that seen
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
2. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
5. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
6. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
7. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
10. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
11. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... -- Numotion is pleased to announce the appointment of Mark ... Mark is a 30-year retired veteran of GE where ... and was a GE Company Officer since 1999 and a ... running business units within GE Healthcare, with the most recent ... "We are delighted to welcome Mark to our Board," ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25
... Tenn., Nov. 18, 2011 MedSolutions , ... services, today announced the launch of its Implantable ... evidence-based guidelines to ensure the clinical appropriateness of ... With the cost of each ICD/CRT-D ...
... Md., Nov. 18, 2011 The U.S. Food and ... ) to treat patients with acute lymphoblastic leukemia (ALL), ... coli derived asparaginase and pegaspargase chemotherapy drugs used ... ) Acute lymphoblastic leukemia is a ...
Cached Medicine Technology:MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 2MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 3FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:9/3/2014)... CA (PRWEB) September 03, 2014 AttorneyOne.com, a ... the latest information from the FDA on Pedigree nutrition ... August 26, that 22 bags of Pedigree Adult Complete Nutrition ... the possible presence of a foreign material. The reason for ... fragments, which could have entered the packages during the production ...
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... September 03, 2014 Pwnie Express today ... cutting edge Pwn Plug, the R3, an inconspicuous pentesting ... of use at remote locations at a fraction of ... Pwnie Express is the only company to assess wired ... Plug R3 is a next-generation penetration testing device in ...
(Date:9/3/2014)... "What can you say about a sixteen-year-old girl who ... Eight in the Margaret of Greenwich (R) Young Adult ... Books, Inc . These novels narrate the lives of a ... in America. , In this thriller, learning geometry becomes the ... student’s murder plot. Her fears increase when Erika, the only ...
(Date:9/2/2014)... dry eye disease include the sensation of grit in ... disturbance. The causes are poorly understood., The researchers base ... 87 (average age 57) from the TwinsUK cohort, drawn ... London., This cohort is widely regarded as representative of ... look at a wide range of diseases and genetic ...
Breaking Medicine News(10 mins):Health News:Pedigree Adult Complete Nutrition for Dogs Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... THURSDAY, March 1 (HealthDay News) -- Where a bird lives ... city dwellers tweeting at a higher pitch than those residing ... recordings, researchers from the University of Copenhagen in Denmark and ... they sing due to city buildings -- not just the ...
... megakaryocytes giant blood cells that produce wound-healing platelets manage ... The findings, to be published March 13 in the journal ... this process may cause a form of leukemia. "A failure ... megakaryoblastic leukemias," said Diane Krause, senior author of the paper, who ...
... THURSDAY, March 1 (HealthDay News) -- Scientists studying mice ... the ability to momentarily retain and utilize information needed ... the March 2 print issue of Cell , ... impairs memory by affecting passive support cells known as ...
... past few decades, doctors have noted a surprising trend ... tongue. Though oral cancer previously appeared predominantly in elderly ... it,s increasing in younger patients: 30- to 50-year-old nonsmokers ... of cancer tends to be less aggressive, and the ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... help people with the rare bone marrow disorder called myelofibrosis. ... the brand name Jakafi, won,t cure myelofibrosis, it can help ... according to the studies. "This is probably the ...
... Aging does not appear to be a factor in poor ... fact, subjective sleep quality seems to improve over a lifetime, with ... flies in the face of popular belief," said Michael Grandner, PhD, ... what we know about sleep in older people men and ...
Cached Medicine News:Health News:City Birds Sing Differently Than Their Country Cousins 2Health News:How red blood cells get so big -- and the bad things that happen when they don't 2Health News:Mayo Clinic: Robotic surgery proves successful, less invasive way to treat HPV-related oral cancer 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Study: Sleep gets better with age, not worse 2
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: